Vantrexa · SCLC · Germany · Oncology pharmacist · captured by James Whitfield on 01 Apr 2026 · reviewed by Dr. Priya Raman on 04 Apr 2026
Verbatim as captured; never edited
Oncology pharmacist at Charité Berlin raised elderly / ecog 2 patients during a scientific exchange. They noted that colleagues in their network share the view.
Human-approved by Dr. Priya Raman on 04 Apr 2026
Elderly / ECOG 2 patients: practice variation observed reported by oncology pharmacist (DE).
helixor-private-llm-2026.05 · generated 01 Apr 2026, 10:00 UTC
AI summary
Elderly / ECOG 2 patients raised by oncology pharmacist; relevant for HEOR.
Source spans used by the model
Oncology pharmacist at Charité Berlin raised elderly / ecog 2 patients during a scientific exchange. They noted that colleagues in their network share the view.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Evidence gap | Evidence gap |
| Function | HEOR | HEOR |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 5 | 20% | 20.0 |
| Strategic alignment | 1 | 20% | 4.0 |
| Scientific importance | 5 | 15% | 15.0 |
| Urgency | 1 | 15% | 3.0 |
| Novelty | 3 | 10% | 6.0 |
| Actionability | 1 | 10% | 2.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | Medium 55 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
01 Apr 2026 · Dr. Emiko Vogel, Charité Berlin · MSL James Whitfield
Insight
Reviewed 04 Apr 2026 by Dr. Priya Raman
Action
Initiative
Decision
Outcome
Closure
Shared with Clinical Development; no further action required.